Yellow fever vaccine

Noreen A. Hynes, M.D., M.P.H., D.T.M.&H., Edina Avdic, Pharm.D.
Yellow fever vaccine is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

-- The first section of this topic is shown below --


General Identification

Live, attenuated yellow fever virus

Vaccine Strain Characteristics

  • The only approved vaccine for use world-wide is a live, attenuated virus derived from the original lot, 17D yellow fever virus strain, created by passing the wild-type virus repeatedly in cultures attenuate its virulent properties while ensuring it would induce immunity to the virus in vaccine recipient.
    • There are two 17D strains in use today (with 99.9% sequence homology)[11]
      • 17D-204: found in the US licensed vaccine (YF-VaxTM)
      • 17DD: manufactured in Brazil
  • The attenuation process used minced chick embryo cultures (no brain or spinal cords included), and the final passage prior to human use was in embyronated eggs.
  • The vaccine is comprised of a quasi-species as the vaccines are not plaque-purified and contain heterogeneous sub-populations with differing mouse-brain neurovirulence.

Non-Virus Constituents in the Vaccine

  • No antibiotics or preservatives are part of any yellow fever vaccine manufactured worldwide.
  • Vaccine is lyophilized for storage and must be reconstituted before use.
    • Must be administered within 60 minutes of reconstitution to insure potency and to avoid bacterial contamination.
  • Manufacturer variability: salt, buffers, and stabilizer excipients.
    • Stabilizers are needed to maintain potency.
      • UK and U.S.: sorbitol and porcine gelatin for stabilization.
      • France: sugars, amino acids, and divalent cations for stabilization.

Viremia following 17D Yellow Fever Vaccination

  • 17D vaccine induces minimal virus titers in circulating blood as opposed to the high virus titers seen in natural yellow fever virus infection.
    • Similar onset to natural infection: ~ day 4 following inoculation, ends about time of neutralizing antibody appearance day 8 or 9 (see Immune Response below).
  • Vaccine titers are below threshold for uptake by the mosquito virus vector of yellow fever.
    • Thought to explain the low risk of maternal-fetal transmission and low rates of neurotropic and viscerotropic vaccine adverse effects.

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: October 4, 2016